Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Wnt-Pathway Modulator Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RSPO3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RSPO3 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View RSPO3 Products |
| Gene Delivery | RSPO3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for functional Wnt-reporter assays. |
View RSPO3 Products |
| Benchmark Ab | Anti-RSPO3 (Sequence of Rosmantuzumab) Recombinant positive control antibody for binding and functional blockade. |
View RSPO3 Products |
| Validator | RSPO3 siRNA Set For knockdown verification in target-validation assays. |
View RSPO3 Products |
| Related Target A | LGR5 The primary functional receptor for RSPO3, mediating Wnt/beta-catenin potentiation. |
View LGR5 Products |
| Related Target B | ZNRF3 E3 ubiquitin ligase cleared by RSPO3-LGR5 interaction to stabilize Wnt receptors. |
View ZNRF3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Preserving Native Glycosylation for Receptor Binding | HEK293 mammalian expression ensures correct post-translational modifications. |
| Off-Target Subfamily Screening (RSPO1/2/4) | Homolog panel proteins strictly verified by mass spectrometry and sequence analysis. |
| Lack of Controls | Clinical Benchmark Antibodies (Rosmantuzumab biosimilar) included |
| False Positives | Validated siRNA included for specificity checks |
Live RSPO3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RSPO3 therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific antibodies and targeted delivery systems. As first-generation therapies (such as Rosmantuzumab) reach clinical evaluation, the next wave of R&D is targeting RSPO3-overexpressing tumors and gene-fusion-driven colorectal cancers (e.g., PTPRK-RSPO3 fusions) while mitigating systemic Wnt-pathway toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | OncoMed, Celgene | Colorectal Cancer, Solid Tumors | Binding Affinity Assay (Need high-purity, natively glycosylated RSPO3 ECD) |
| Bispecific Antibody | Academic & Biopharma Consortia | Wnt-driven Malignancies | Dual-Targeting Validation (Need RSPO3 and LGR5/LGR6 recombinant proteins) |
| Small Molecule Inhibitors | Preclinical Discovery Programs | Fibrotic Diseases, Oncology | In vitro Screening (Need stable cell lines via RSPO3 Lentivirus) |